Metastatic Colorectal Cancer
Conditions
Brief summary
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with colorectal cancer.
Detailed description
This is a study for the patients with colorectal cancer. Maximum tolerated dose climbing test is expected into the group of 9 cases of patients. And Phase II expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. Subjects will be collected their T cells and modify them, the modification is a genetic change, that EGFR:4-1BB:CD28:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects. Fourth generation CART, also known as TRUCKs (T cells redirected for universal cytokine before), mainly in order to improve the effect of solid tumor treatment and design, through NFAT transcription factors inducing expression of IL - 12, overcome the solid tumor within the tumor microenvironment of CART limit the function of cellsThe purpose of this study is observe the MTD and to assess the safety and feasibility of CART cells in the patients with metastatic colorectal cancer.
Interventions
BIOLOGICALEGFR IL12 CART
EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
Sponsors
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Shenzhen Second People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients must be 18 years to 70 years; 2. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer; 3. Patients must have a KPS of \>80, expected survival \> 3 months; 4. Patients must have at least one measurable lesions; 5. Recently did not use glucocorticoid; 6. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: WBC ≥ 3.0×109/L, Hb ≥90 g/L, PLT ≥100×109/L）; AST ≤2.5ULN，ALT ≤ 2.5ULN; Cr≤ 3ULN; TBIL≤ 3ULN， 7. Patients must have a good heart function (LVEF\>50%) ; 8. Patients must be willing to practice birth control during and for three months following treatment.NOTE:female participants of reproductive potential must have a negative serum pregnancy test, and willing to practice birth control during and for three months following treatment； 9. Patients must be willing to sign an informed consent.
Exclusion criteria
1. Patients with other cancer history; 2. Patients allergic to cetuximab; 3. Patients with severe bronchitis, bronchial asthma, or severs pneumonia; 4. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ; 5. Patients with acute and chronic GVHD (graft versus host disease) 6. Patients with severe autoimmune diseases; 7. Previously treatment with T cell inhibitors (cyclophosphamide, FK506); 8. Patients with active hepatitis B or hepatitis C infection, HIV infection, syphilis serology reaction positive; 9. Patients who are participating or participated any other clinical research in the past 1 months; 10. Pregnant and/or lactating women will be excluded; -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Occurrence of study related adverse events | 24 weeks | Occurrence of study related adverse events as assessed by CTCAE v4.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness: Changes of tumor markers | 24 weeks | Changes of tumor markers CA-199, AFP and CEA |
| Effectiveness: duration of in vivo survival of EGFR CART | 1 year | Determine duration of in vivo survival of EGFR CART |
Countries
China
Outcome results
None listed